RAG-17 is an experimental RNA-targeting therapy designed to lower toxic SOD1 protein in people with SOD1-ALS. A six-person trial found RAG-17 was well tolerated, with no serious side effects. RAG-17 ...
The Muscular Dystrophy Association (MDA) brought its Engage Community Seminar to Hershey, Pennsylvania, on July 18, uniting ...
While the findings align with previous research linking smoking to ALS, researchers found no consistent evidence that heavier ...
An AI-powered brain implant helped an ALS patient regain speech by decoding brain signals. This neuroprosthesis translates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results